Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion.

Sieber CC, Beglinger C, Bart S, Tschoepl M, Currie G, Larsen F, Drewe J

Clinical pharmacology and therapeutics1 Jan 2004Cited by 5 (Europe PMC)

PMID14749693DOI10.1016/j.clpt.2003.09.006PepBankPUB-14749693

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialPharmacokinetics
In healthy subjects, lanreotide infusion and bolus were bioequivalent: AUC 1844.3 versus 1971.0 ng.min/L, ratio 0.99, confidence interval 0.95-1.02.
In plain wordsIn healthy subjects, lanreotide infusion and bolus produced equivalent overall drug exposure.
Peptide
Lanreotide
Outcome
Not applicableAUC bioequivalence
Study
n = 12
Comparator
lanreotide bolus injection
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100 microg/h infusion for 8 hours versus 800-microg bolus · intravenousAs given in this study (human).
Measurements
AUC extrapolated to infinity
1844.3 ng.min/L
100 microg/h lanreotide infusion
AUC extrapolated to infinity
1971 ng.min/L
800 microg lanreotide bolus
AUC(infinity) ratio
0.99 ratio
infusion versus bolus
95% confidence interval of AUC(infinity) ratio
0.95 to 1.02 ratio
infusion versus bolus
Source sentences
Summary
Lanreotide as a 100-microg/h infusion for 8 hours was bioequivalent with lanreotide as an 800-microg bolus injection (mean area under the plasma concentration-time curve [AUC] extrapolated to infinity [AUC( infinity )], 1844.3 ng.min/L versus 1971.0 ng.min/L; AUC(infinity) ratios, 0.99; confidence interval, 0.95-1.02)
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve healthy subjects (6 men and 6 women) were studied in a double-blind, double-dummy, randomized, crossover study.
Summary · context
After a baseline period of 60 minutes, each subject received either a placebo bolus injection and an intravenous infusion of 100 microg/h lanreotide over a period of 8 hours or a placebo infusion over a period of 8 hours and an 800-microg lanreotide bolus injection.
Report a problemFND-1474969301
02HumanRandomized controlled trialPharmacokinetics
In healthy subjects, lanreotide clearance was identical with infusion and bolus: 479.2 versus 413.4 mL/min (P >.05).
In plain wordsIn healthy subjects, lanreotide clearance did not differ significantly between infusion and bolus.
Peptide
Lanreotide
Outcome
No significant changeClearance
Study
n = 12
Comparator
lanreotide bolus injection
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100 microg/h infusion for 8 hours versus 800-microg bolus · intravenousAs given in this study (human).
Measurements
clearance
479.2 mL/min
100 microg/h lanreotide infusion
clearance
413.4 mL/min
800 microg lanreotide bolus
Source sentences
Summary
and clearance was identical (479.2 mL/min versus 413.4 mL/min, P >.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve healthy subjects (6 men and 6 women) were studied in a double-blind, double-dummy, randomized, crossover study.
Summary · context
After a baseline period of 60 minutes, each subject received either a placebo bolus injection and an intravenous infusion of 100 microg/h lanreotide over a period of 8 hours or a placebo infusion over a period of 8 hours and an 800-microg lanreotide bolus injection.
Report a problemFND-1474969302
03HumanRandomized controlled trialPharmacokinetics
In healthy subjects, maximum lanreotide concentrations differed between infusion and bolus: 75.58 versus 4.85 ng/mL, respectively (P <.001).
In plain wordsIn healthy subjects, maximum lanreotide concentrations differed between infusion and bolus.
Peptide
Lanreotide
Outcome
IncreaseMaximum plasma concentration
Study
n = 12
Comparator
lanreotide bolus injection
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
100 microg/h infusion for 8 hours versus 800-microg bolus · intravenousAs given in this study (human).
Measurements
maximum plasma concentration
75.58 ng/mL
after 100 microg/h lanreotide infusion
maximum plasma concentration
4.85 ng/mL
after 800 microg lanreotide bolus
Source sentences
Summary
As expected, significant differences were observed in maximum plasma concentrations (75.58 ng/mL versus 4.85 ng/mL, P <.001) after infusion and bolus injections, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve healthy subjects (6 men and 6 women) were studied in a double-blind, double-dummy, randomized, crossover study.
Summary · context
After a baseline period of 60 minutes, each subject received either a placebo bolus injection and an intravenous infusion of 100 microg/h lanreotide over a period of 8 hours or a placebo infusion over a period of 8 hours and an 800-microg lanreotide bolus injection.
Report a problemFND-1474969303
04HumanRandomized controlled trialEfficacy outcome
In healthy subjects, lanreotide infusion abolished food-stimulated superior mesenteric hyperemia, whereas bolus only temporarily blunted it: AUC 37.25 versus 251.4 L/min.min.
In plain wordsIn healthy subjects, lanreotide infusion suppressed food-stimulated intestinal artery blood flow more persistently than bolus.
Peptide
Lanreotide
Outcome
DecreaseSuperior mesenteric hyperemia
Study
n = 12
Comparator
lanreotide bolus injection
Outcome group
Vascular function · Cardiovascular
Studied dose
100 microg/h infusion for 8 hours versus 800-microg bolus · intravenousAs given in this study (human).
Measurements
mean AUC above baseline, superior mesenteric artery
37.25 L/min.min
100 microg/h lanreotide infusion
mean AUC above baseline, superior mesenteric artery
251.4 L/min.min
800 microg lanreotide bolus
Source sentences
Summary
Lanreotide at 100 microg/h over a period of 8 hours was well tolerated and abolished food-stimulated splanchnic hyperemia in both the superior mesenteric artery and the portal vein (mean AUC above baseline values [AUC(ab)], 37.25 L/min.min and 0.51 L/min.min, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
In contrast, the same dose of lanreotide given as a bolus injection only temporarily blunted postprandial hyperemia (mean AUC(ab) for superior mesenteric artery, 251.4 L/min.min, P <.001;
Summary · context
Twelve healthy subjects (6 men and 6 women) were studied in a double-blind, double-dummy, randomized, crossover study.
Summary · context
After a baseline period of 60 minutes, each subject received either a placebo bolus injection and an intravenous infusion of 100 microg/h lanreotide over a period of 8 hours or a placebo infusion over a period of 8 hours and an 800-microg lanreotide bolus injection.
Report a problemFND-1474969304
05HumanRandomized controlled trialEfficacy outcome
In healthy subjects, lanreotide infusion abolished food-stimulated portal hyperemia, whereas bolus only temporarily blunted it: AUC 0.51 versus 194.95 L/min.min.
In plain wordsIn healthy subjects, lanreotide infusion suppressed food-stimulated portal vein blood flow more persistently than bolus.
Peptide
Lanreotide
Outcome
DecreasePortal venous hyperemia
Study
n = 12
Comparator
lanreotide bolus injection
Outcome group
Vascular function · Cardiovascular
Studied dose
100 microg/h infusion for 8 hours versus 800-microg bolus · intravenousAs given in this study (human).
Measurements
mean AUC above baseline, portal vein
0.51 L/min.min
100 microg/h lanreotide infusion
mean AUC above baseline, portal vein
194.95 L/min.min
800 microg lanreotide bolus
Source sentences
Summary
Lanreotide at 100 microg/h over a period of 8 hours was well tolerated and abolished food-stimulated splanchnic hyperemia in both the superior mesenteric artery and the portal vein (mean AUC above baseline values [AUC(ab)], 37.25 L/min.min and 0.51 L/min.min, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
In contrast, the same dose of lanreotide given as a bolus injection only temporarily blunted postprandial hyperemia (mean AUC(ab) for superior mesenteric artery, 251.4 L/min.min, P <.001; mean AUC(ab) for portal vein, 194.95 L/min.min, P <.001), and subjects had significantly more side effects.
Summary · context
Twelve healthy subjects (6 men and 6 women) were studied in a double-blind, double-dummy, randomized, crossover study.
Summary · context
After a baseline period of 60 minutes, each subject received either a placebo bolus injection and an intravenous infusion of 100 microg/h lanreotide over a period of 8 hours or a placebo infusion over a period of 8 hours and an 800-microg lanreotide bolus injection.
Report a problemFND-1474969305
06HumanRandomized controlled trialSafety outcome
In healthy subjects, lanreotide infusion was well tolerated, while bolus caused significantly more side effects.
In plain wordsIn healthy subjects, lanreotide bolus caused more side effects than infusion.
Peptide
Lanreotide
Outcome
DecreaseSide effects
Study
n = 12
Comparator
lanreotide bolus injection
Outcome group
Adverse events · Whole body
Studied dose
100 microg/h infusion for 8 hours versus 800-microg bolus · intravenousAs given in this study (human).
Source sentences
Summary
In contrast, the same dose of lanreotide given as a bolus injection only temporarily blunted postprandial hyperemia (mean AUC(ab) for superior mesenteric artery, 251.4 L/min.min, P <.001; mean AUC(ab) for portal vein, 194.95 L/min.min, P <.001), and subjects had significantly more side effects.
3 context sentences(design, population, supporting numbers)
Summary · context
Lanreotide at 100 microg/h over a period of 8 hours was well tolerated and abolished food-stimulated splanchnic hyperemia in both the superior mesenteric artery and the portal vein (mean AUC above baseline values [AUC(ab)], 37.25 L/min.min and 0.51 L/min.min, respectively).
Summary · context
Twelve healthy subjects (6 men and 6 women) were studied in a double-blind, double-dummy, randomized, crossover study.
Summary · context
After a baseline period of 60 minutes, each subject received either a placebo bolus injection and an intravenous infusion of 100 microg/h lanreotide over a period of 8 hours or a placebo infusion over a period of 8 hours and an 800-microg lanreotide bolus injection.
Report a problemFND-1474969306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.